Clinical Trials
21 trialsNCT01356290 2026-02-23
MEMMAT
Medical University of Vienna
Phase 2 Recruiting
NCT01661400 2024-01-31
ASCR
Washington University School of Medicine
Phase 1 Completed
NCT00014443 2023-01-09
Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma
Rush University Medical Center
Phase 2 Terminated
NCT00112502 2021-10-18
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00049361 2021-09-09
Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases
Wake Forest University Health Sciences
Phase 2 Completed
NCT00079092 2021-09-09
Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
Wake Forest University Health Sciences
Phase 2 Completed
NCT00033254 2020-10-30
Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Phase 3 Completed
NCT00527657 2018-11-14
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00006358 2018-06-26
Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00047281 2017-07-11
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00047294 2017-07-11
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00098865 2014-10-07
Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00357500 2014-10-01
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01756989 2014-05-08
ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors
Helsinki University Central Hospital
Phase 2 Completed
NCT00072163 2013-01-17
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00412542 2012-02-28
Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00039468 2011-10-27
Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00047879 2011-10-26
Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00049296 2010-06-11
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00251797 2010-01-07
A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors
University of New Mexico
Phase 1 Completed
NCT00521482 2007-08-28
Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma
University of Zurich
Phase 2 Unknown